NASDAQ OMX

Mitratech Yields Accolades as Market Leader and Innovator by Analyst Firm Hyperion Research

Dela

Powerful "zero-code" product configuration, expansive user experience enhancements, and upgrades-included program set Mitratech's TeamConnect apart from other solution providers

AUSTIN, Texas, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Mitratech, a leading provider of legal, compliance, and risk management software solutions, today announced that its enterprise legal management (ELM) products have earned distinctions as Market Leaders and Highly Innovative products in the 2017 MarketView(TM) Report on Enterprise Legal Management by Hyperion Research, a leading analyst-based market research firm covering the ELM market.

Mitratech's years of investment in TeamConnect continues to deliver strong results - being one of the strongest products in the ELM market with top rankings across many of the rating categories in the MarketView(TM) Report. TeamConnect is the only ELM platform in the industry that includes code-free customizations, saving its clients significant time and money. And, its one-of-a-kind "upgrades-included" program demonstrates the company's true commitment to client success.

According to Hyperion, "TeamConnect, driven by aggressive development and a holistic vision of ELM in recent years, is one of the leading systems serving the enterprise market."1

"We are honored to be recognized as a Market Leader once again," said Mitratech CEO Jason Parkman. "We made the decision four years ago to pull ahead of all other ELM providers by offering something no one else can. It was a significant investment that is paying off for our clients today."

TeamConnect is one of three Mitratech products to make Hyperion's top ten and qualify as Advanced Solutions. Each Advanced Solution met all of Hyperion's Key Solution Components - fundamental requirements that define leading ELM practices for both e-billing and matter management. Twenty-three corporate legal department software products were evaluated with an opportunity to qualify for this distinction.

Hyperion validated Mitratech's vision to develop products that enable increased collaboration and communication between legal, compliance and risk professionals: "One of the things that distinguishes Mitratech from its competitors is its espoused worldview of ELM. Management contextualizes the discipline as part of a larger Governance, Risk and Compliance (GRC) universe, where risk management is perhaps as important as, or more important than, operational efficiency,"2 stated Hyperion.

Hyperion Research's MarketView(TM) report provides a comprehensive review of the broad market for Enterprise Legal Management technologies. The report provides a guidebook for ELM system evaluation, including market trends and dynamics, key components expected from leading solutions, an overview of vendors in the solution area, and guiding principles for selecting and implementing solutions.

The full report is available for download on the Hyperion website. For more information about Mitratech's products and services, visit www.mitratech.com.

ABOUT MITRATECH
Mitratech is a market-leading provider of legal, compliance, and risk software solutions for more than 1,200 organizations of all sizes across the globe, representing almost 40 percent of the Fortune 500, and over 500,000 users in over 160 countries. Mitratech's portfolio of enterprise legal and risk management software includes: legal matter management, spend management, e-Billing, legal hold, contracts management, risk management, policy management, audit management, and health & safety management. To learn more, visit www.mitratech.com.

ABOUT HYPERION RESEARCH
Hyperion Research is the industry's leading source for Legal Solutions Market Intelligence. We work with law firms, law departments and other legal service organizations to make intelligent, fact-based decisions about how to improve their operational performance. The profession's leaders, innovators and trend-makers have come to rely on Hyperion Research as the premier provider of independent market research, analysis and advisory services. We provide unparalleled insight to the leading trends in legal strategy, operations, and technology. Hyperion's analyst-based research and benchmarking informs 8 out of every 10 practice management system selections each year. For more information, visit www.hgpresearch.com.

__________________________________
1 2017, MarketView Legal Market Intelligence, Enterprise Legal Management E-Billing and Matter Management for Corporations, (page 100), Hyperion Research (elm.hgp-marketview.com).
2 2017, MarketView Legal Market Intelligence, Enterprise Legal Management E-Billing and Matter Management for Corporations, (page 101), Hyperion Research (elm.hgp-marketview.com).

Mitratech

Chris Kraft

512-382-7322




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mitratech via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum